Publication of Resolve's Phase 2a Lupus Trial Outcomes

On February 12, 2024, Resolve Therapeutics, a biotech firm in the clinical development phase, revealed the findings of a phase 2a clinical trial for a new treatment called RSLV-132, aimed at patients with Systemic Lupus Erythematosus (SLE). The study, published in "Lupus Science & Medicine," focused on the effects of RNase therapy on patients with moderate to severe skin manifestations of SLE. The results indicated that patients with higher SLEDAI-2k scores, a measure of lupus disease activity, showed a greater response to the treatment, which involves the breakdown of extracellular RNA.
Dr. James Posada, CEO of Resolve Therapeutics, expressed appreciation to the participants and highlighted the growing body of research that underscores the significance of extracellular RNA in autoimmune diseases like SLE and Sjogren's syndrome. The study's findings point to the possible therapeutic benefits of eliminating circulating pathogenic RNA in certain SLE patients with active systemic disease and autoantibodies that contain RNA.
RSLV-132 is a biologic medication that combines human RNase1 with the Fc region of human IgG1. It is engineered to circulate in the blood and degrade extracellular RNA, which is a key instigator of interferon production and chronic inflammation in autoimmune diseases. By removing RNA from the bloodstream, RSLV-132 may reduce inflammation and alleviate the symptoms of these conditions.
Resolve Therapeutics is a private company that is innovating a novel method for treating autoimmune diseases. The firm is building on scientific research that has established the pivotal role of pathogenic RNA in these diseases. RSLV-132 is currently in the midst of clinical development for several conditions, including SLE, Sjogren's syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC). The company's efforts are part of a broader initiative to address the significant medical needs in the field of autoimmune disease treatment.